JPWO2019222188A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019222188A5
JPWO2019222188A5 JP2020564674A JP2020564674A JPWO2019222188A5 JP WO2019222188 A5 JPWO2019222188 A5 JP WO2019222188A5 JP 2020564674 A JP2020564674 A JP 2020564674A JP 2020564674 A JP2020564674 A JP 2020564674A JP WO2019222188 A5 JPWO2019222188 A5 JP WO2019222188A5
Authority
JP
Japan
Prior art keywords
icos
cells
agonist
seq
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020564674A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523213A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/032184 external-priority patent/WO2019222188A1/en
Publication of JP2021523213A publication Critical patent/JP2021523213A/ja
Publication of JPWO2019222188A5 publication Critical patent/JPWO2019222188A5/ja
Pending legal-status Critical Current

Links

JP2020564674A 2018-05-14 2019-05-14 癌を治療する方法 Pending JP2021523213A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862671181P 2018-05-14 2018-05-14
US62/671,181 2018-05-14
US201862679346P 2018-06-01 2018-06-01
US62/679,346 2018-06-01
US201862750026P 2018-10-24 2018-10-24
US62/750,026 2018-10-24
US201962827312P 2019-04-01 2019-04-01
US62/827,312 2019-04-01
PCT/US2019/032184 WO2019222188A1 (en) 2018-05-14 2019-05-14 Methods of treating cancer

Publications (2)

Publication Number Publication Date
JP2021523213A JP2021523213A (ja) 2021-09-02
JPWO2019222188A5 true JPWO2019222188A5 (ru) 2022-05-20

Family

ID=66690990

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020564674A Pending JP2021523213A (ja) 2018-05-14 2019-05-14 癌を治療する方法

Country Status (5)

Country Link
US (2) US11292840B2 (ru)
EP (1) EP3793598A1 (ru)
JP (1) JP2021523213A (ru)
CN (1) CN112703012A (ru)
WO (1) WO2019222188A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10980804B2 (en) 2013-01-18 2021-04-20 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US20200024351A1 (en) * 2017-04-03 2020-01-23 Jounce Therapeutics, Inc. Compositions and Methods for the Treatment of Cancer
EP3870610A1 (en) * 2018-10-24 2021-09-01 Jounce Therapeutics, Inc. Methods and compositions for the treatment of cancer and infectious diseases
US20230089426A1 (en) * 2020-01-13 2023-03-23 Jounce Therapeutics, Inc. Methods for the treatment of cancer
EP4139358A1 (en) * 2020-04-20 2023-03-01 Jounce Therapeutics, Inc. Compositions and methods for vaccination and the treatment of infectious diseases
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
CN112807425A (zh) * 2021-01-14 2021-05-18 南方医科大学深圳医院 一种tTIM融合蛋白疫苗、制备方法及应用
CA3219336A1 (en) 2021-05-18 2022-11-24 Kymab Limited Uses of anti-icos antibodies
WO2023222854A1 (en) 2022-05-18 2023-11-23 Kymab Limited Uses of anti-icos antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO2012131004A2 (en) 2011-03-31 2012-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies directed against icos and uses thereof
US10034939B2 (en) 2012-10-26 2018-07-31 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
ES2733546T3 (es) 2013-03-15 2019-11-29 Bristol Myers Squibb Co Inhibidores de IDO
CN107530428B (zh) 2015-03-23 2022-05-13 震动疗法股份有限公司 Icos的抗体
AU2016342269A1 (en) 2015-10-22 2018-03-29 Jounce Therapeutics, Inc. Gene signatures for determining icos expression
WO2018029474A2 (en) * 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
CN116640214A (zh) 2016-08-09 2023-08-25 科马布有限公司 分离抗体及其应用

Similar Documents

Publication Publication Date Title
Ishikawa et al. Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with I g G 1 antibody in patients with gastric or colorectal cancer
RU2017137020A (ru) Антитела к icos
Seystahl et al. Therapeutic options in recurrent glioblastoma—An update
JP5642328B2 (ja) Nk細胞増強化合物を使用する治療抗体の有効性を増大させる方法および組成物
AU2017249698B2 (en) Ex vivo bite-activated T cells
Ohata et al. Mycophenolic acid inhibits natural killer cell proliferation and cytotoxic function: a possible disadvantage of including mycophenolate mofetil in the graft-versus-host disease prophylaxis regimen
Piotrowicz et al. A6 peptide activates CD44 adhesive activity, induces FAK and MEK phosphorylation, and inhibits the migration and metastasis of CD44-expressing cells
WO2018102785A2 (en) Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
JPWO2019222188A5 (ru)
Magalhaes et al. CD19 chimeric antigen receptor T cells from patients with chronic lymphocytic leukemia display an elevated IFN-γ production profile
WO2017205213A1 (en) Combination therapy of abemaciclib and immune checkpoint modulators for use in the treatment of cancer
CN114222758A (zh) 抗bcma抗体及其在car-t领域中的应用
Jiang et al. Addressing patient to patient variability for autologous CAR T therapies
CN110520539A (zh) 预测抗癌药的临床结果的方法
Nakase et al. Elevated levels of soluble interleukin-2 receptor in serum of patients with hematological or non-hematological malignancies
Maharaj et al. Differential regulation of human T-cells by TGR-1202, a novel PI3Kδ inhibitor
EP4058805B1 (en) Anti-clever-1 agents for controlling the expression of cell surface markers on leucocytes, and using these to guide anti-clever-1 based cancer treatment
CN113073079A (zh) 增强活性的nk免疫细胞在制备治疗癌症的药物中的用途
Madi et al. CD8 agonism functionally activates memory T cells and enhances antitumor immunity
Ma et al. Automatic generation of lymphocyte heterogeneity: Division‐dependent changes in the expression of CD27, CCR7 and CD45 by activated human naive CD4+ T cells are independently regulated
Wang et al. SIRP-alpha-IL-6 axis induces immunosuppressive macrophages in non-small-cell lung cancer
US20240053360A1 (en) Methods of selectively targeting cd6 high cells and decreasing activity of teff cells
Sato et al. Adoptive γδT-cell transfer alone or combined with chemotherapy for the treatment of advanced esophageal cancer
Novitzky et al. Definition of the variables affecting efficacy of immunodepletion ex vivo of peripheral blood progenitor cell grafts by alemtuzumab (Campath in the bag)
US20240158869A1 (en) Factors for optimizing immunotherapy